1.30
79.36%
+0.5752
After Hours:
1.22
-0.08
-6.15%
Biodexa Pharmaceuticals Plc ADR stock is currently priced at $1.30, with a 24-hour trading volume of 70.29M.
It has seen a +79.36% increased in the last 24 hours and a +62.24% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.7116 pivot point. If it approaches the $0.8232 resistance level, significant changes may occur.
Previous Close:
$0.7248
Open:
$1.66
24h Volume:
70.29M
Market Cap:
$5.70M
Revenue:
$644.60K
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.00155
EPS:
-837.9618
Net Cash Flow:
$-9.02M
1W Performance:
+72.87%
1M Performance:
+62.24%
6M Performance:
-67.01%
1Y Performance:
+400.19%
Biodexa Pharmaceuticals Plc ADR Stock (BDRX) Company Profile
Name
Biodexa Pharmaceuticals Plc ADR
Sector
Industry
Phone
44 29 2048 0180
Address
1 Caspian Point, Caspian Way, Cardiff
Biodexa Pharmaceuticals Plc ADR Stock (BDRX) Latest News
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
GlobeNewswire Inc.
Preliminary Results for the Year Ended 31 December 2023
GlobeNewswire Inc.
Here’s How Global Events Impact Penny Stocks
PennyStocks
Is Market Cap an Important Penny Stocks Trading Factor?
PennyStocks
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Biodexa Pharmaceuticals Plc ADR Stock (BDRX) Financials Data
Biodexa Pharmaceuticals Plc ADR (BDRX) Revenue 2024
BDRX reported a revenue (TTM) of $644.60 thousand for the quarter ending June 30, 2023, a -18.55% decline year-over-year.
Biodexa Pharmaceuticals Plc ADR (BDRX) Net Income 2024
BDRX net income (TTM) was -$9.87 million for the quarter ending June 30, 2023, a +7.77% increase year-over-year.
Biodexa Pharmaceuticals Plc ADR (BDRX) Cash Flow 2024
BDRX recorded a free cash flow (TTM) of -$9.02 million for the quarter ending June 30, 2023, a -17.38% decrease year-over-year.
Biodexa Pharmaceuticals Plc ADR (BDRX) Earnings per Share 2024
BDRX earnings per share (TTM) was -$837.96 for the quarter ending June 30, 2023, a +38.26% growth year-over-year.
About Biodexa Pharmaceuticals Plc ADR
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Cap:
|
Volume (24h):